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Abstract. The rapid and reversible upregulation of the 
functional activity of integrin receptors on T lympho- 
cytes is a vital step in the adhesive interactions that oc- 
cur during successful T cell recognition of foreign anti- 
gen and transendothelial migration. Although the 
ligation of several different cell surface receptors, in- 
cluding the antigen-specific CD3/T cell receptor com- 
plex, the CD2, CD7, and CD28 antigens, as well as sev- 
eral chemokine receptors, has been shown to rapidly 
upregulate integrin function, the intracellular signaling 
events that initiate this increase in adhesion remain 
poorly defined. In this study, we have used DNA-medi- 
ated gene transfer to explore the role of phosphatidyl- 
inositol 3-kinase (PI 3-K) in the upregulation of 131 in- 
tegrin functional activity mediated by the CD2 antigen. 
CD2 was expressed in the myelomonocytic  cell line 
HL60, which expresses 131 integrins that mediate adhe- 
sion to fibronectin and VCAM-1 in an activation- 
dependent manner. Antibody stimulation of CD2 ex- 
pressed on HL60 transfectants resulted within minutes 
in increased 131-mediated adhesion to fibronectin and 
VCAM-1 at levels comparable to that obtained upon 
stimulation with the phorbol ester PMA. A role for PI 
3-K in CD2-mediated increases in 131 integrin function 
is suggested by: (a) the ability of the PI 3-K inhibitor 
wortmannin to completely inhibit CD2-induced in- 
creases in 131 integrin activity; (b) the association of PI 
3-K with CD2; and (c) induced PI 3-K activity upon 
CD2 stimulation. The mode of association of PI 3-K 
with CD2 is not mediated by tyrosine phosphorylation- 
dependent binding of PI 3-K via SH2 domains, since: 
(a) PI 3-K is associated with CD2 in unstimulated cells; 
(b) CD2 stimulation fails to increase the amount of as- 
sociated PI 3-K; and (c) the CD2 cytoplasmic domain 
lacks tyrosine residues. A role for both protein kinase 
C and cytoskeletal rearrangements in CD2 regulation 
of integrin activity is also suggested, since a PKC inhib- 
itor partially inhibits CD2-induced increases in 131 inte- 
grin function, and CD2 stimulation increases F-actin 
content in a wortmannin-sensitive manner. Analysis of 
human peripheral T cells indicated that CD2 stimula- 
tion also results in PI 3-K-dependent upregulation of 
131 integrin activity. Thus, these results demonstrate 
that CD2 can function as an adhesion regulator in the 
absence of expression of the CD3/T cell receptor com- 
plex; and directly implicate PI 3-K as a critical intracel- 
lular mediator involved in the regulation of 131 integrin 
functional activity by the CD2 antigen. 
T 
HE precise  regulation of the interaction of immune 
cells, such  as T  lymphocytes, with other cells and 
with components of the extracellular matrix (ECM)  1 
is vital to the successful response of the immune system to 
a foreign challenge. Integrin adhesion receptors are a ma- 
jor group of adhesion molecules used by circulating leuko- 
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cytes to interact with and respond to the extraceUular en- 
vironment (32, 67). Since the primary function of a T cell 
involves recirculation in an ongoing search for foreign an- 
tigen,  it is not surprising  that T cells use several  mecha- 
nisms  of regulating integrin receptor  functional activity 
(41). One major mode of regulating integrin function that 
is used by T cells as well as other circulating leukocytes in- 
volves a rapid increase  in integrin functional activity after 
activation of the cell  (17, 63, 78). Thus, while human T 
cells  bind poorly to most integrin ligands  and counter- 
receptors, such  as the LFA-1 counter-receptor ICAM-1, 
the et4131 counter-receptor VCAM-1,  and the ct4131 and 
t~5~l ECM ligand fibronectin (FN), activation quickly in- 
creases  integrin-mediated T cell function (17, 60, 62, 63, 
70, 78, 82). Such activation-dependent upregulation of in- 
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recognition of foreign antigen by T cells, by serving to rap- 
idly strengthen the interaction between T cells and anti- 
gen-presenting ceils (17,  62);  and (b) T  cell recirculation 
and migration into inflammatory sites. Recent multi-step 
models of leukocyte interactions with endothelium pro- 
pose that integrin upregulation represents the mechanism 
by which stable shear-resistant adhesion of leukocytes with 
endothelium is initiated and maintained (68). Consequently, 
further analysis of the  mechanisms by which  activation 
regulates integrin activity is essential to our overall under- 
standing of the immune response. 
Activation-dependent upregulation of integrin activity 
is  characterized  by  several  features.  First,  activation- 
induced increases in integrin activity occur rapidly, typi- 
cally within seconds to  minutes after activation  (17,  63, 
78).  Second, activation induces changes in integrin func- 
tional activity, as measured by adhesion to relevant ligands 
or counter-receptors, without a change in the level of cell 
surface integrin expression (17, 63, 78). This suggests some 
qualitative alteration in the integrin receptor itself, such as 
a conformational change that alters the affinity of an inte- 
grin for a ligand, and/or cellular responses, such as recep- 
tor  microclustering,  that  alter  the  avidity  of  integrin- 
dependent  cellular interactions (18,  37).  Third,  multiple 
different receptors on a lymphocyte are capable of deliver- 
ing a  signal that upregulates integrin activity. We define 
such molecules as "integrin regulators." On T cells, the list 
of known integrin regulators is now quite extensive and 
minimally includes the antigen-specific CD3/T cell recep- 
tor complex, CD2, CD7, CD28, CD31, as well as receptors 
for chemokines, such as MIP-I[3 and hepatocyte growth 
factor (1, 17, 61, 63, 71, 72, 78). Despite the growing list of 
known integrin regulators on T cells, the intracellular sig- 
nals generated upon engagement of these molecules that 
lead to integrin upregulation remain poorly defined. The 
ability of pharmacologic agents such as the phorbol ester 
PMA and Ca  ~+ ionophore to upregulate integrin activity 
implicates both protein kinase C (PKC) and intracellular 
calcium with this regulatory event (17, 61, 63, 82). Studies 
with  signal  transduction  inhibitors  have  implicated  ty- 
rosine kinases, protein kinase A, and G proteins in activa- 
tion-dependent integrin upregulation (4, 12, 17, 61). How- 
ever, it is not clear whether all of the integrin regulators 
expressed on a given cell use common or distinct signaling 
pathways to mediate integrin upregulation. 
The present study focuses on an analysis of the intracel- 
lular signals generated by the  CD2  antigen that lead to 
upregulation of 131 integrin activity. The CD2 antigen is a 
45-55-kD  glycoprotein that is a member of the immuno- 
globulin superfamily (8). Structurally, CD2 has two extra- 
cellular immunoglobulin-like domains, a  transmembrane 
domain and a ll6-amino acid cytoplasmic domain rich in 
proline residues (55). Early studies of CD2 function on T 
cells demonstrated that unique pairs of CD2-specific mono- 
clonal antibodies (mAbs) can induce T cell proliferation in 
the  absence  of engagement of the  CD3/T  cell receptor 
(39).  Subsequent studies by many laboratories have dem- 
onstrated that CD2 stimulation can induce IL-2 produc- 
tion (7), the activation of PLC--y1 (46), PKC (2), and p21 raS 
(20),  as well as increased tyrosine kinase activity (54),  in- 
tracellular calcium (81), and intracellular cyclic AMP (26). 
Analysis of CD2 in T  cells has also suggested that CD2- 
mediated signaling is dependent on expression of the anti- 
gen-specific CD3/T cell receptor (9), which is consistent 
with reports that CD2 on T  cells is physically associated 
with components of the T  cell receptor complex (5,  10). 
CD2 is itself an adhesion molecule, capable of mediating T 
cell adhesion to other cells by binding to three different 
counter-receptors, CD58 (LFA-3), CD48, and CD59 (24, 
35, 56). Furthermore, activation of T cells via the CD3/T 
cell receptor can also increase CD2-mediated adhesion to 
CD58, although the mechanism by which this occurs ap- 
pears to be somewhat distinct from CD3/T cell receptor- 
mediated upregulation of integrin activity (23, 27).  Struc- 
ture-function analysis of the CD2 cytoplasmic domain has 
revealed regions of the cytoplasmic domain important for 
CD2-induced  production  of IL-2  as  well  as  CD3/TCR- 
mediated regulation of CD2 adhesion to CD58 (6, 13, 14, 
22, 27). With regard to its role as an integrin regulator, ac- 
tivating pairs of CD2-specific mAbs have been shown to 
result within minutes in increased adhesion of human pe- 
ripheral T cells and CD2 ÷ human T cell lines to ICAM-1, 
FN, and laminin (40, 63, 78). 
Phosphatidylinositol 3-kinase (PI 3-K) is an intracellular 
enzyme that phosphorylates the D-3 position of the inosi- 
tol ring of phosphatidylinositol (PI), phosphatidylinositol- 
4-phosphate,  and  phosphatidylinositol-4,5-bisphosphate. 
PI 3-K activity has been shown to be activated by a wide 
range  of growth factors, oncogenes and other nonmito- 
genic  stimuli  (34).  A  wide  variety of cellular functions 
appear to be dependent on PI 3-K, including growth fac- 
tor-dependent  mitogenesis, cytoskeletal rearrangements, 
glucose uptake, prevention of apoptosis, cytokine produc- 
tion, and endocytic trafficking (33, 34, 45, 83). The signal- 
ing pathways initiated by PI 3-K remain poorly defined, 
although recent studies have suggested that the lipid prod- 
ucts generated by PI 3-K activity can activate certain iso- 
forms of PKC in vitro (44, 73). 
Structurally, PI 3-K consists of two subunits, pll0 and 
p85. The p110 subunit is the catalytic subunit that contains 
a  lipid kinase domain. The p85  subunit contains several 
amino acid motifs that allow for the association of PI 3-K 
with cytoplasmic receptors  to  form signaling complexes 
(47).  The most well-described mode of association of PI 
3-K with upstream signaling receptors occurs via tyrosine 
phosphorylation-dependent association  of PI  3-K  medi- 
ated by src-homology 2 (SH2) domains found on the p85 
subunit (47).  SH2-mediated binding of PI 3-K to multiple 
receptors has been demonstrated, including the platelet- 
derived growth factor (PDGF) receptor (30),  the epider- 
mal growth factor receptor (30), the major insulin receptor 
substrate IRS-1 (3), CD19 (76), and CD28 (45, 51, 74). The 
functional significance of this interaction has been demon- 
strated by the findings that: (a) SH2-mediated binding of 
p85 to receptors can activate PI 3-K (11, 43); (b) mutation 
of the SH2-binding motif in the PDGF-R inhibits PDGF- 
mediated mitogenesis (77) as well as PDGF-R internaliza- 
tion (33); and (c) mutation of the SH2-binding motif in the 
CD28  cytoplasmic domain inhibits  CD28-mediated  pro- 
duction of IL-2 (45).  The p85  subunit also contains pro- 
line-rich sequences  capable  of mediating the binding of 
proteins containing SH3 domains (47). The SH3 domains 
of the intracellular tyrosine kinases abl, Ick, fyn,  and lyn 
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p85 subunit (48, 52, 80). Finally, the p85 subunit itself con- 
tains  an SH3  domain,  and in vitro studies  have demon- 
strated SH3-dependent binding of p85 to proline-rich se- 
quences in the motor protein dynamin (19). Thus, the p85 
subunit of PI 3-K contains several structural motifs that al- 
low PI 3-K to be coupled to a multitude of cell surface and 
intracellular molecules. 
In this study, we demonstrate a  role for PI 3-K in the 
regulation of [31 integrin activity mediated by the integrin 
regulator CD2. We used DNA-mediated gene transfer to 
express this T  cell integrin regulator in a non-T cell line, 
the myelomonocytic cell line HL60. Stimulation of CD2 
expressed on HL60 cells was shown to result in increased 
131  integrin-mediated adhesion of CD2 + transfectants to 
the 131 integrin ligands FN and VCAM-1. Increased 1~1 in- 
tegrin activity mediated by CD2 stimulation but not PMA 
stimulation was completely inhibited by the PI 3-K inhibi- 
tor  wortmannin.  Furthermore,  biochemical  experiments 
demonstrated that while PI 3-K is associated with CD2 in 
both unstimulated and CD2-stimulated cells, PI 3-K activ- 
ity associated with CD2 was detectable only in CD2-stimu- 
lated cells. Analysis of peripheral CD2 ÷ T  cells revealed 
that  CD2 stimulation also resulted in PI 3-K-dependent 
upregulation of 131 integrin activity. Thus, these results not 
only demonstrate a role for PI 3-K in CD2-mediated up- 
regulation of 131 integrin activity but also highlight a po- 
tentially novel mode of association and  activation of PI 
3-K with CD2. 
Materials and Methods 
Cell Lines and Culture Reagents 
The cell lines HL60, U937, and K562 were maintained in RPMI 1640 me- 
dium supplemented with 5% FCS (Sigma Chemical Co., St. Louis, MO), 
L-glutamine, and  penicillin/streptomycin.  During  G418  selection  after 
electroporation, the concentration of FCS was increased to  10%.  G418 
was purchased from GIBCO BRL (Gaithersburg, MD). 
Human T  cells were isolated by negative magnetic immunoselection 
from peripheral blood as previously described (29). The T cell populations 
obtained were routinely >98% CD3+CD2 + as assessed by flow cytomet- 
ric analysis. 
Antibodies and Other Reagents 
The CD2-specific mAb 95-5-49 (53) (Dr. R. Gress, NIH, Bethesda, MD) 
was used as purified IgG for adhesion assays and as culture supernatants 
for  screening of HL60  transfectants by  flow  cytometry. The  following 
mAbs were  used as dilutions of ascites fluid:  CD2-specific mAbs 35.1 
(American Type Culture  Collection  [ATCC],  Rockville,  MD)  and  9-1 
(provided by Dr. S. Y. Yang, Memorial Sloan Kettering Cancer Center, 
New York, NY), a2-specific mAb P1E6 and ¢t3-specific  mAb P1B5 (both 
GIBCO  BRL), a4-specific mAbs L25  (38)  (provided  by Dr.  P. Estess, 
Becton-Dickinson, Mountain View, CA) and NIH49d-1 (provided by Dr. 
S. Shaw, NIH, Bethesda, MD), 131-specific mAb P4C10 (GIBCO BRL), 
activating 131-specific mAb P4Gll  (provided by Dr. E. A. Wayner), and 
the LFA-1 ct chain-specific mAb TS1/22 (ATCC). The ct5-specific mAb 
BIIG2 (provided by Dr. C. Damsky, University of California, San Fran- 
cisco, CA) and the cd-specific mAb TS2/7 (ATCC) were used as culture 
supernatants. The LFA-1  [3 chain-specific mAb MHM23  (Dr.  S.  Shaw, 
NIH, Bethesda, MD), the a6-specific mAb GoH-3 (Immunotech, West- 
brook,  ME), and the 131-specific mAb B-D15  (Biosource International, 
Camarillo, CA) were used as purified IgG. The p85-specific polyclonal an- 
tibody was obtained from Upstate Biotechnology (Lake Placid, NY). 
FN was purchased from the New York Blood Center (New York, NY). 
Chinese Hamster Ovary cells expressing a soluble form of VCAM-1 (49) 
were kindly provided by Dr. W. Newman (Otsuka America Pharmaceuti- 
cals, Rockville, MD). VCAM-1 was purified by affinity chromatography 
using the VCAM-l-speciflc mAb 2G7 as previously described (79). Stock 
solutions of wortmannin (purchased from Sigma Chemical Co.),  PMA 
(LC Services Corp., Woburn, MA) and bisindolylmaleimide (Calbiochem 
Novabiochem, La  Jolla,  CA)  were  dissolved in  DMSO  and  stored  at 
-70°C. 
DNA-mediated Gene Transfer 
The full-length CD2 cDNA clone (55) (provided by Drs. B. Seed and C. 
Romeo,  Massachusetts General  Hospital,  Boston, MA) was  subcloned 
into the pMH-NeoH plasmid expression vector. This vector is identical to 
the pMH-Neo vector (25) (provided by Dr. B. Bierer, Dana-Farber Can- 
cer Institute, Boston, MA), except that the HindlII site in the multiple 
cloning site has been eliminated by site-directed mutagenesis. The result- 
ing construct (designated pMH-NeoH-CD2) was transfected into HL60 
cells by electroporation.  Briefly, 107 HL60 cells were washed once with 
HeBS buffer (20 mM Hepes pH 7.05~ 137 mM NaC1, 5 mM KC1, 0.7 mM 
NazHPO4, 6 mM dextrose) and resuspended in 0.8 ml of ice-cold HeBS 
containing 20 I~g of uncut DNA. Electroporation was performed with a 
Bio-Rad Gene Pulser set to 280V, 960 ~F, resulting in a time constant of 
11.9 ms. After electroporation, cells were allowed to sit on ice for 10 min 
before being diluted into 24 ml of RPMI/10%  FCS and aliquoted into a 
single 24-well tissue culture plate. After 4 d of cell recovery, selection was 
initiated by the addition of RPMI/10% FCS medium containing 1 mg/ml 
G418 (0.5 ml/well). Every 4 d thereafter, 0.5 ml of medium was removed 
from each well and replaced  with 0.5 ml of fresh G418-containing me- 
dium. Screening for CD2 + transfectants was performed 20-24 d after the 
electroporation. 
To isolate CD2 ÷ subclones, bulk transfectant populations were first en- 
riched for CD2 ÷ cells by panning. Briefly, 6-well tissue culture plates were 
incubated overnight at 4°C with PBS containing 10 ixg/ml  of goat anti- 
mouse IgG (Organon Teknika, Malvern, PA). After the overnight incuba- 
tion, plates were washed twice with PBS and incubated for 1-2 h at 37°C 
with PBS containing 2.5%  BSA. Transfectants were washed once with 
PBS containing 0.5% human serum albumin (PBS/HSA) and then incu- 
bated in 1 ml of PBS/HSA containing 2-3 ~g of the CD2-speciflc mAb 95- 
5-49 for 30 min at 4°C. Cells were then washed twice with PBS/HSA, re- 
suspended in 1.5 ml of PBS/HSA, added directly to the GAM-IgG-coated 
6-well plates, and incubated for 2 h  at 4°C. Nonadherent cells were re- 
moved by washing the plates three times with PBS, and RPMI/10% FCS 
medium containing 1 mg/ml G418 added to the wells to allow for expan- 
sion of the adherent cells. These bulk populations of transfectants were 
subsequently cloned by limiting dilution and screened for CD2 expression 
by  flow  cytometry.  Representative  subclones were  chosen for  further 
analysis. 
Flow Cytometry 
Single-color flow cytometry was performed as previously described (64) 
using saturating amounts of primary unlabeled mAb and detection with 
goat anti-mouse IgG FITC (Southern Biotechnology, Birmingham, AL). 
Samples were analyzed on a FACScan (Becton Dickinson). 
Adhesion Assays 
Adhesion assays were performed essentially as described before (42) with 
the exception of washing procedures.  Briefly,  96-well microtiter  plates 
(Costar No. 3596, Cambridge, MA) were incubated overnight at 4°C with 
the indicated concentrations of FN or VCAM-1 (diluted in PBS with Ca  2+ 
and Mg  2+) and unbound protein binding sites subsequently blocked with 
PBS/2.5% BSA. Each well contained 50,000 51Cr-labeled HL60 cells in a 
final volume of 0.1 ml PBS/HSA. For PMA activation, cells were added to 
wells containing 10 ng/ml PMA. For CD2 stimulation, cells were added to 
wells containing 10 i~g/ml of the CD2-specific mAb 95-5-49 and either a 
1:6,000 dilution of the CD2-specific mAb 9-1 (for HL60 transfectants) or a 
1:1,000  dilution  of  9-1  (for  peripheral  T  cells);  this  combination  of 
CD2-specific mAbs has been previously demonstrated to induce T  cell 
proliferation (65) and to result in increased 131- and 132-integrin-mediated 
adhesion of T  cells to FN and laminin (40, 63). We refer to this pair of 
CD2-specific mAbs throughout this manuscript as the activating combina- 
tion  of  CD2-specific mAbs. Integrin-specific antibodies  and  inhibitors 
(wortmannin and bisindolylmaleimide) were added to wells before the ad- 
dition of cells and used at the concentrations indicated in the figure leg- 
ends. After 1 h settling at 4°C, plates were rapidly warmed to 37°C for 10 
Shimizu et aL PI 3-K and CD2 Adhesion Regulation  1869 min and then the nonadherent cells washed off with four washes using a 
microplate  washer  (EIA04;  Bio-tek  Instruments, Winooski, VT).  The 
washer was set to the following settings: 200 ixl dispense volume, 0 cycles, 
0 s soak time, 085 aspiration depth, "Yes" for final aspiration after wash, 
20 s shake time, and 14 shake frequency. The pressure pump was set to 3 
psi and the vacuum pump gauge was set to 7 in of Hg. The plate was ro- 
tated 180  ° between each wash. The percentage of bound cells was deter- 
mined by lysing the well contents with detergent and counting ~-emis- 
sions. All data are expressed as the mean percent of cells binding from 
three replicate wells. 
Immunoblotting 
Immunoblotting experiments were  conducted  as  previously  described 
(12).  Cell samples (107 cells/sample) were treated as described in the leg- 
end to Fig. 8 for the indicated time periods and then lysed in PI 3-K lysis 
buffer (50 mM Hepes, pH 7.5, 1% Triton X-100, 150 mM NaCl, 10% glyc- 
erol, 1.5 mM MgC12, 1 mM EGTA) supplemented with 10 ixg/ml aproti- 
nin, 10 ixg/ml leupeptin, 1 mM PMSF, and 1 mM sodium orthovanadate. 
Cell lysates were incubated on ice for 10 min at 4°C and then centrifuged 
at 4°C for 30 min at 11,000 g. Immunoprecipitations were performed by in- 
cubating cell  lysates overnight on a  rotator  with goat anti-mouse IgG- 
Sepharose beads precoated with the CD2-specific mAb 35.1. The immu- 
noprecipitating beads were then washed twice with PI 3-K lysis buffer and 
finally resuspended in 50 Ixl SDS sample buffer. 40 p~l of each sample was 
separated on a 7.5% SDS-polyacrylamide gel and transferred to nitrocel- 
lulose membrane. Blocking of the membrane was performed overnight at 
4°C in PBS/2% BSA. The blot was then washed twice for 15 min each with 
PBS/0.1% Tween, incubated with the antibody specific for the p85 subunit 
of PI 3-K (1:2,000  dilution in PBS/2% BSA) for I h at room temperature, 
washed four times (10 min each wash) with PBS/0.1% Tween, and incu- 
bated  with  horseradish peroxidase-conjugated donkey  anti-rabbit  IgG 
(Amersham,  Arlington  Heights,  IL)  (1:5,000  dilution  in  PBS/0.1% 
Tween) for I h at room temperature. After six washes (10 min each) with 
PBS/0.1%  Tween, p85  was detected using the enhanced chemilumines- 
cence (ECL) system (Amersham). Similar results were obtained when 1× 
modified RIPA buffer (150 mM NaCl, 50 mM Tris-C1 pH 7.5,  1% NP40, 
0.25% sodium deoxycholate, 1 mM sodium orthovanadate, 2 mM EDTA) 
was used to solubilize the cells. 
PI 3-K Assays 
Cells (2  ×  107 cells/sample) were stimulated, lysed and immunoprecipi- 
tated as described in the immunoblotting assay protocol.  PI 3-K assays 
were performed essentially as previously described (31).  Briefly, lysates 
were immunoprecipitated with either the CD2-specific mAb 35.1 coupled 
to goat anti-mouse IgG Sepharose beads or the p85-specific mAb coupled 
to protein A-Sepharose. The immunoprecipitates were washed twice with 
PI 3-K lysis buffer, once with 0.5  M  LiC1, 0.1  M  Tris, pH 7.5  (supple- 
mented with 10 ~g/ml aprotinin, 10 p~g/ml leupeptin, 1 mM PMSF, and 1 
mM sodium orthovanadate), and once with 10 mM Tris, pH 7.5, 0.1 mM 
EDTA, 0.1 M NaC1 (supplemented with inhibitors as above). The immu- 
noprecipitates were then resuspended in 50 I~l of kinase buffer (20 mM 
Tris, pH 7.5, 75 mM NaC1, 10 mM MgC12, 20 mM Hepes, pH 7.5, and 200 
~M adenosine) and 1 ~.l of sonicated phosphatidylinositol (20 mg/ml dis- 
solved in DMSO) was added. The kinase reaction was initiated by adding 
10 p.Ci of ~/-32p-labeled  ATP and 10 ~M ATP to each tube and incubating 
at room temperature for 20 min. The reaction was terminated by adding 
100  Ixl of chloroform/methanol/HC1 (100:200:2).  An additional 100 ~1 of 
chloroform and 100 ~1 of water was added, the tubes vortexed and centri- 
fuged for 5 min at 11,000 g. The organic phase was collected, dried, and re- 
suspended in 25 izl of chloroform/methanol (1:1)  containing phosphati- 
dylinositol-4-phosphate as a standard, and spotted on a silica gel 60 thin 
layer chromatography plate. Chromatography was performed in chloro- 
form/methanol/ammonia/water (43:38:5:7) and the labeled phosphatidylino- 
sitol was detected by autoradiography. 
Actin Polymerization 
Changes in actin polymerization upon CD2 stimulation were assessed es- 
sentially as previously described (1). Briefly, duplicate samples of cells (1 x 
106 cells/sample in a  volume of 0.9 ml PBS/HSA) were either unstimu- 
lated, stimulated with 10 ng/ml PMA, or stimulated with the activating 
combination of CD2-specific mAbs for 10 min at 37°C in the absence or 
presence of 100 nM wortmannin. After stimulation, cells were permeabi- 
lized by adding 100  Ixl of a  1 mg/ml solution of lysophosphatidylcholine 
(Sigma) in 37% formalin and incubating for 10 min at 37°C. After perme- 
abilization, 25 p.l of a 6.6 fxM stock of BODIPY-FL phallacidin (Molecu- 
lar Probes, Eugene, OR) was added and the samples incubated for an ad- 
ditional 10 min at 37°C.  Samples were then centrifuged, resuspended in 
ice-cold HBSS and analyzed on a FACScan. The mean channel fluores- 
cence from each of the two duplicate samples was averaged and then nor- 
malized to the average mean channel fluorescence of unstimulated cells in 
the absence of wortmannin. 
Results 
fll Integrin Expression and Function on HL60 Cells 
The goal of this study was to develop a system where the 
integrin regulatory signaling properties of the CD2 anti- 
gen could be reconstituted by gene transfer in a CD2- cell 
line that also lacks expression of the CD3/T cell receptor 
complex. We reasoned that the  recipient cell line to be 
used in these experiments needed to minimally fulfill the 
following three requirements. First, the cell line must lack 
expression of human CD2. Second, the cell line must ex- 
press functional [31 integrins. Third, the 131 integrins ex- 
pressed on this cell line must exhibit activation-dependent 
increases in function, as typically observed in peripheral 
human T cells and several T cell lines (40, 59, 62, 63). In- 
creased  [31  integrin  function  upon  stimulation  with  the 
phorbol ester PMA was used as the criteria for fulfillment 
of this third requirement. 
After  screening multiple  human  non-T cell  lines  and 
mouse T  cell hybridomas, several human cell lines were 
identified that fulfilled the above criteria. These included 
the erythroleukemia cell line K562, and myelomonocytic 
cell lines U937 and HL60. All three of these cell lines lack 
expression of CD2 (Fig. 1 and data not shown). The HL60 
cell line was chosen for these studies because its pattern of 
131 integrin expression most closely resembled that found 
on human peripheral blood T cells (40, 63): no detectable 
(x1131 and  c~2131, low but  detectable  levels of a3131 and 
(x6131 and clearly detectable levels of et4131 and et5131 (Fig. 
LOG FLUORESCENCE 
Figure 1.  131 integrin expression on HL60 cells. Single color flow 
cytometric analysis was performed as described in Materials and 
Methods. Filled histograms in each panel represent expression of 
the indicated  antigen.  Open histograms represent negative con- 
trol staining of HL60 cells in the absence of a  primary antibody 
and is shown in each panel for ease of comparison. Specific pri- 
mary antibodies used were:  131-specific mAb  P4C10,  or-specific 
mAb TS2/7, ct2-specific mAb P1E6, o~3-specific mAb P1B5, CD2- 
specific  mAb  95-5-49,  ~x4-specific  mAb  NIH49d-1,  a5-specific 
mAb P1D6, and ct6-specific mAb GoH-3. 
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Figure 2.  Stimulation with PMA results in rapid upregulation of 
131-mediated adhesion of HL60 cells to FN. In A, binding of 51Cr- 
labeled unstimulated  (squares) HL60 cells or HL60 cells stimu- 
lated for 10 min at 37°C with 10 ng/ml PMA (circles) to various 
doses of FN was assessed as described in Materials and Methods. 
In B, the specificity  of HL60 binding to FN (applied at 0.3 I~g/ 
well) was assessed  by testing the ability of the following mAbs to 
inhibit the binding of unstimulated (shaded bars) and PMA-stim- 
ulated (solid bars) cells to FN: the a4-specific mAb L25, the a5- 
specific mAb BIIG2, the 131-specific  mAb P4C10, the non-block- 
ing a4-specific mAb NIH49d-1, and the LFA-1 13 chain-specific 
1).  In adhesion assays, unstimulated  HL60 cells bound at 
low levels to various doses of the 131 integrin ECM ligand 
FN (Fig. 2).  More significantly, stimulation  of HL60 cells 
for 10 min at 37°C with PMA resulted in increased adhe- 
sion of HL60 cells to FN (Fig. 2 A). Monoclonal antibody 
blocking studies  indicated  that  the  adhesion  of unstimu- 
lated  and  PMA-stimulated  HL60  cells  was  131-specific, 
since  a  [M-specific  mAb  completely  inhibited  adhesion 
(Fig.  2  B).  Analysis with  a  chain-specific  mAbs showed 
that  an c~4-specific mAb by itself was not appreciably in- 
hibitory while an a5-specific mAb by itself completely in- 
hibited  binding  of unstimulated  HL60  cells  but  did  not 
completely inhibit binding of PMA-stimulated HL60 cells. 
A  role for a4131 in HL60 adhesion  to FN is indicated  by 
the ability of the combination of c~4- and a5-specific mAbs 
to inhibit the binding of PMA-stimulated HL60 cells to FN 
as  effectively as  the  131-specific  mAb.  Thus,  as  observed 
previously with human T  cells (63), HL60 adhesion to FN 
is mediated  by both the a4131  and a5131 integrins,  with  a 
predominant contribution by the a5131 integrin (Fig. 2 B). 
Expression of CD2 on HL60 Cells 
Results in CD2-stimulated Increases in HL60 [31 
Integrin Function 
To investigate  the function of CD2 as an integrin regula- 
tor,  DNA-mediated  gene  transfer  was  used  to  express 
CD2 in the HL60 cell line. Fig. 3 shows that transfection of 
a full-length human CD2 cDNA resulted in detectable lev- 
els of CD2 on the surface of G418-resistant transfectants. 
Levels of CD2 expression varied but several transfectants 
were obtained that expressed CD2 at levels comparable to 
that found on the CD2 ÷ T  cell line Jurkat (Fig. 3 and data 
not shown). We chose two transfectants for further analy- 
sis: HL60(CD2)-ll.5,  which expresses CD2 at levels com- 
parable  to  Jurkat  cells,  and  HL60(CD2)-23.9,  which  ex- 
presses lower levels of CD2 than either the 11.5 transfectant 
or Jurkat  cells.  All transfectants  tested  had  levels  of [M, 
c~4, and a5 comparable to untransfected HL60 cells (Fig. 3 
and data not shown). 
Unique pairs of CD2-specific mAbs have been shown to 
activate human T  cells, as measured by cellular prolifera- 
tion,  cytokine production and increases  in integrin-medi- 
ated adhesion (7, 39, 40, 63, 78). We have previously dem- 
onstrated  that  incubation  of either  peripheral  human  T 
cells or human T  cell lines, such as Jurkat, with the combi- 
nation  of the  CD2-specific mAbs 95-5-49 and  9-1  results 
within  minutes  in  increased  adhesion  to various  integrin 
ligands  and  counter-receptors  (40,  63).  Stimulation  of 
CD2 ÷ HL60 transfectants with this activating combination 
of CD2-specific mAbs also resulted in increased HL60 ad- 
hesion to FN (Fig. 4). For the 11.5 transfectant, which ex- 
presses CD2 at levels comparable to the Jurkat T  cell line, 
the integrin  adhesion regulatory signal provided by CD2 
stimulation  was  as  effective  as  PMA  stimulation  at  all 
doses of FN tested.  The CD2 adhesion response was pre- 
mAb MHM23. All mAbs were used at a concentration of 10 Ixg/ 
ml, except for BIIG2, which was used at a 1:10 dilution of culture 
supernatant.  Binding to the negative control ECM protein col- 
lagen was <2% under all activation conditions tested.  Data shown 
are representative of a minimum of five different experiments. 
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Figure 3.  CD2  expression on CD2 ÷ HL60 transfectants. Single 
color flow cytometric analysis was performed as described in Ma- 
terials and Methods. Binding of the CD2-specific mAb 95-5-49 
(left column)  and the [31-specific mAb B1-D5 (right column)  is 
shown as filled histograms in each panel. Open histograms repre- 
sent negative control staining of cells in the absence of a primary 
antibody and  is shown  in  each  panel for  ease of comparison. 
HL60(CD2)-ll.5  and  HL60(CD2)-23.9  are  two  representative 
transfectants of HL60 cells expressing high (11.5) and intermedi- 
ate (23.9) levels of CD2. CD2 and [31 integrin expression on the 
CD2 ÷ human T cell line Jurkat is shown to illustrate the level of 
CD2 expression on HL60 transfectants compared to a human cell 
that normally expresses CD2. 
dictably less efficient in the HL60(CD2)-23.9  transfectant 
(Fig.  4),  which  expresses  lower  levels  of  CD2  than  the 
HL60(CD2)-ll.5  transfectant,  although  binding of CD2- 
stimulated cells was  still higher than  that  observed with 
unstimulated cells. As observed in T  cells, CD2-mediated 
increases  in  adhesion  to  FN  were  not  observed  when 
transfectants  were  stimulated  with  only one  of  the  two 
CD2-specific mAbs (Fig. 4). 
Although PMA stimulation results in increased binding 
of HL60 cells to FN via both the a4131 and ~5131 integrins 
(Figs. 2 B  and 5), similar antibody blocking studies using 
CD2-stimulated  CD2 ÷  HL60  transfectants  suggest  that 
CD2 stimulation results in preferential upregulation of a5131 
relative to a4131. Thus, while an a5-specific mAb only par- 
tially inhibits the binding of PMA-stimulated CD2 ÷ trans- 
fectants to FN, the same a5-specific mAb completely in- 
hibits the binding of CD2-stimulated transfectants to FN 
(Fig. 5). 
To  determine whether  CD2  stimulation also results in 
increased a4131-mediated adhesion, the binding of CD2 ÷ 
HL60 transfectants to the a4[M cell surface counter-recep- 
tor VCAM-1 was assessed. Fig. 6 shows that while unstim- 
ulated  HL60  cells and  CD2 +  HL60  transfectants  fail to 
bind to various doses of affinity-purified VCAM-1, PMA- 
stimulation increases the binding to VCAM-1 of all three 
cell lines tested. For the  11.5  transfectant  that  expresses 
levels of CD2 comparable to human T  cells, CD2 stimula- 
tion results in increased adhesion to VCAM-1 comparable 
to that seen after PMA-stimulation. Interestingly, the 23.9 
transfectant that expresses lower levels of CD2  does not 
show increased adhesion to VCAM-1  after CD2 stimula- 
tion except at the highest dose of VCAM-1 tested (Fig. 6). 
Since the level of et4131 integrin expression on the 11.5 and 
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Figure  4.  Antibody stimula- 
tion of CD2 results in upreg- 
ulation of adhesion of CD2 ÷ 
HL60  transfectants  to  FN. 
Binding of HL60 cells (left), 
and the CD2 ÷ HL60 transfec- 
tants  HL60(CD2)-ll.5  (mid- 
d/e)  and  HL60(CD2)-23.9 
(right) to various doses of FN 
was assessed in the presence 
of:  no  stimulus  (solid  cir- 
cles),  10  ng/ml  PMA  (solid 
squares),  activating combina- 
tion  of  CD2-specific  mAbs 
(triangles),  10  Ixg/ml  of the 
CD2-specific  mAb  95-5-49 
alone (open  circles),  or a  1: 
6,000  dilution  of  the  CD2- 
specific mAb 9-1 alone (open 
squares).  Cells  were  acti- 
vated for 10 min at 37°C be- 
fore washing  away the  non- 
adherent cells. Binding to the 
negative  control  ECM  pro- 
tein collagen was <1.5% un- 
der all activation conditions 
tested.  Data are representa- 
tive of a minimum of five dif- 
ferent experiments. 
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inhibited by a5- and 131-specific mAbs. Binding of unstimulated 
(open bars), PMA-stimulated (shaded bars), and CD2-stimulated 
(solid bars) HL60(CD2)-ll.5 transfectants to FN (applied at 0.3 
txg/well) was assessed  in the presence of the following mAbs: c~4- 
specific  mAb  L25,  ~x5-specific mAb  BIIG2,  [M-specific  mAb 
P4C10, non-blocking a4-specific mAb NIH49d-1, and the LFA-1 
c~-chain-specific mAb TS1/22. MAbs were used at the concentra- 
tions indicated in the legend to Fig. 2. PMA was used at a concen- 
tration of 10 ng/ml,  and the activating combination of CD2-spe- 
cific mAbs consisted of 10 ixg/ml of 95-5-49 and a 1:6,000 dilution 
of 9-1. Activation was for 10 min at 37°C. Binding to the negative 
control ECM protein collagen was <3 % under all activation con- 
ditions tested. Data are representative of a minimum of four dif- 
ferent experiments. 
the 23.9 transfectants was comparable (Fig. 3 and data not 
shown), this  suggests  that the level of CD2 expression  is 
particularly  critical  for  CD2-induced  increases  in  tx4131 
functional activity. 
The PI3-K Inhibitor Wortmannin Inhibits CD2 
Adhesion Regulation in HL60 Transfectants 
The fungal metabolite wortmannin has recently been shown 
to be a highly specific inhibitor of PI 3-K when used at nano- 
molar  concentrations  (15,  50,  57).  Fig.  7  A  shows  that 
treatment  of the  11.5  transfectant  with  100  nM  of wort- 
mannin  completely  inhibits  the  ability  of the  activating 
combination of CD2-specific mAbs to upregulate 131 inte- 
grin-mediated adhesion to FN. The specificity of the inhib- 
itory  effects  for  CD2-mediated  upregulation  of integrin 
function is suggested by the minimal effects of wortmannin 
on adhesion induced by PMA stimulation (Fig. 7 A) or the 
activating 131-specific  mAb P4Gll  (data not shown). Dose 
response studies indicate that the half-maximal concentra- 
tion  (ICs0)  of wortmannin  that  inhibits  CD2-induced  in- 
creases in  CD2 + HL60 transfectant  adhesion  to FN is in 
the range of 30-40 nM (Fig. 7 B). This ICs0 value is consis- 
tent with  concentrations  of wortmannin  found to specifi- 
cally inhibit PI 3-K-dependent cellular responses and PI 3-K 
activity in other systems (15, 57). Thus, these results  sug- 
gest that the signal transduced by CD2 stimulation that re- 
sults in upregulation of [31 integrin function in HL60 trans- 
fectants is dependent on PI 3-K. 
Constitutive Association of CD2 with PI 3-K 
The  ability  of  wortmannin  to  inhibit  CD2-induced  in- 
creases  in  [31 integrin  functional  activity on CD2 ÷ HL60 
transfectants  suggested  an  association  between  the  CD2 
antigen and PI 3-K. Since PI 3-K has not previously been 
shown to be associated with CD2, we tested this hypothe- 
sis by immunoprecipitating the CD2 antigen from unstim- 
ulated, CD2-stimulated,  and PMA-stimulated  CD2 ÷ HL60 
transfectants and assessing the presence of the p85 subunit 
of PI 3-K in CD2 immunoprecipitates by immunoblotting. 
Fig. 8 demonstrates that the p85 subunit of PI 3-K can be 
detected in CD2 immunoprecipitates of CD2  + HL60 trans- 
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Figure 6.  Antibody stimula- 
tion  of  CD2  results  in  up- 
regulation  of  adhesion  of 
HL60(CD2)-23.9  CD2 +  HL60  transfectants 
to  the  ct4131 counter-recep- 
tor  VCAM-1.  Binding  of 
HL60  cells  (left),  and  the 
CD2  ÷  HL60  transfectants 
HL60(CD2)-ll.5 (middle) and 
HL60(CD2)-23.9  (right)  to 
various  doses  of  VCAM-1 
was assessed in the presence 
of:  no  stimulus  (circles),  10 
ng/ml PMA (squares), or an 
activating  combination  of 
CD2-specific  mAbs  (trian- 
gles). Cells were activated for 
10 rain at 37°C before wash- 
ing  away  the  nonadherent 
cells. Binding to the negative 
--  --  -  control  ECM  protein  col- 
2.5  5  10  20  lagen was <3% under all ac- 
tivation  conditions  tested. 
Data are representative  of a 
minimum  of three  different 
experiments. 
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Figure 7.  CD2-mediated upregulation of adhesion of CD2 + HL60 transfectants to FN is completely inhibited by the PI 3-K inhibitor 
wortmannin. (A) Binding of HL60(CD2)-11.5  cells to various doses of FN was assessed in the presence of no stimulus (circles), 10 ng/ml 
PMA (triangles), or an activating combination of CD2-specific  mAbs (squares) in the absence (solid symbols) or continuous presence 
(open symbols) of 100 nM wortmannin. Cells were activated for 10 min at 37°C before washing away the nonadherent cells. Data are 
representative of a  minimum of seven different experiments. (B)  The effect  of various doses of wortmannin on the  adhesion of 
HL60(CD2)-11.5  cells to FN (applied at 1 txg/well) after no stimulation (triangles), PMA-stimulation (diamonds) and CD2-stimulation 
(squares) was assessed. Activation conditions were identical to those used in A. Data are representative of a minimum of four different 
experiments. 
Figure 8.  Constitutive association of PI  3-K with CD2.  HLr0 
(CD2)-11.5 cells (107 cells/stimulation condition) were either un- 
stimulated (U), CD2-stimulated for 0, 0.5, 1, 2, 5, and 10 min, or 
PMA-stimulated for 10 min, lysed in PI 3-K lysis buffer, and im- 
munoprecipitated with the CD2-specific  mAb 35.1 as described 
in Materials and Methods. Unstimulated HL60 ceils were also 
prepared in a similar manner. 8 x  10  6 cell equivalents were sepa- 
rated on a 7.5% SDS-polyacrylamide  gel, transferred to nitrocel- 
lulose membrane, and immunoblotted with an antibody specific 
for the p85 subunit of PI 3-K. Data are representative of a mini- 
mum of four different experiments. Similar results were obtained 
when the lysates were prepared using lx modified RIPA buffer 
(see Materials and Methods). 
fectant lysates but no p85 is detected when CD2-specific 
mAbs are used in immunoprecipitation experiments with 
lysates prepared from normal CD2- HL60 cells. 
Two important points should be noted regarding the as- 
sociation of CD2  with p85.  First,  p85  is  associated with 
CD2  expressed  on  unstimulated CD2 +  HL60  transfec- 
tants. Second, stimulation of transfectants with the activat- 
ing combination of CD2-specific mAbs or PMA does not 
increase the amount of p85 associated with CD2. Thus, the 
association of PI 3-K with CD2 appears to be distinct from 
the well-described mode of SH2-mediated binding of p85 
to many other cell surface receptors, where PI 3-K associa- 
tion is dependent on activation-dependent tyrosine phos- 
phorylation  of  the  receptor's  cytoplasmic  domain  (47). 
These results indicate that PI 3-K associates with CD2 ex- 
pressed in HL60 cells in a constitutive activation-indepen- 
dent fashion. 
CD2 Stimulation Results in Activation of PI 3-K 
To more definitively address the significance of the CD2- 
associated  PI  3-K  detected  in  immunoblotting experi- 
ments, we directly tested PI 3-K enzymatic activity in im- 
munoprecipitates of CD2 isolated from unstimulated and 
CD2-stimulated HL60(CD2)-11.5 transfectants. PI 3-K ac- 
tivity in CD2 immunoprecipitates was assessed by testing 
the  ability of CD2 immunoprecipitates to phosphorylate 
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tivation of CD2-associated PI 3-K.  HL60(CD2)-ll.5  cells  (2  x 
107 cells/sample)  were either unstimulated or stimulated with the 
activating combination of CD2-specific mAbs for 10 rain at 37°C, 
lysed in PI 3-K lysis buffer, and then immunoprecipitated with ei- 
ther the CD2-specific mAb 35.1 (left) or a p85-specific  antibody 
(right). Samples were then tested for PI 3-K activity as described 
in Materials  and  Methods,  the  phosphatidylinositol  (P/)  sepa- 
rated by thin layer chromatography and the labeled lipid  prod- 
ucts visualized  by autoradiography. 
phosphatidylinositol in vitro (31). Although PI 3-K is found 
to be  associated  constitutively with  CD2 in  unstimulated 
HL60  transfectants,  there  is  minimal  PI  3-K  activity  in 
CD2 immunoprecipitates from unstimulated cells (Fig. 9). 
In contrast, stimulation of CD2 ÷ HL60 transfectants with 
the activating combination of CD2-specific mAbs induces 
PI 3-K activity in  CD2  immunoprecipitates.  Control im- 
munoprecipitates  using  a  p85-specific  antibody  demon- 
strate that PI 3-K activity can be detected in both unstimu- 
lated  and  CD2-stimulated  cells.  Thus,  even  though CD2 
stimulation fails to increase  the amount of PI 3-K associ- 
ated with CD2, stimulation with CD2-specific mAbs does 
result in increased activity of the associated PI 3-K. These 
results, coupled with the potent inhibitory effects of wort- 
mannin in our adhesion assays, support the hypothesis that 
CD2-mediated  regulation  of 131  integrin  function  occurs 
via a PI 3-K-dependent pathway. 
Partial Inhibition of CD2-mediated Integrin 
Upregulation by PKC Inhibitors 
Although the exact intracellular  responses initiated  by PI 
3-K activation remain poorly defined, several studies have 
recently suggested that the lipid products generated by PI 
3-K activity can activate several isoforms of PKC (44, 73). 
To begin to assess potential downstream effects of PI 3-K- 
dependent  upregulation  of integrin function mediated  by 
CD2 stimulation, we tested the ability of the PKC inhibitor 
bisindolylmaleimide  to  inhibit  CD2-induced  increases  in 
binding to FN. Fig. 10 shows that treatment  of the CD2  ÷ 
11.5  transfectants  with  bisindolylmaleimide  inhibited  ad- 
hesion induced by the activating combination of CD2-spe- 
cific mAbs (Fig. 10). However, at concentrations of bisin- 
dolylmaleimide  (3  and  10  o~M) that  completely inhibited 
the binding of PMA-stimulated  transfectants  to FN, inhi- 
bition of binding of CD2-stimulated cells to FN was only 
partial (Fig. 10). As expected, bisindolylmaleimide had no 
effect  on  adhesion  induced  by  the  activating  131-specific 
mAb P4Gll (Fig. 10). 
Figure 10.  The  PKC inhibi- 
tor bisindolylmaleimide  par- 
tially  inhibits  CD2-mediated 
upregulation  of  adhesion 
of HL60(CD2)-ll.5 transfec- 
tants  to  FN.  Adhesion  of 
HL60(CD2)-ll.5 cells  to FN 
(applied at 1 ~g/well)  in the 
continuous presence of no in- 
hibitor  (PBS/HSA),  DMSO 
control (DMSO), or the PKC 
inhibitor  bisindolylmale- 
imide  (BIS)  at  1,  3,  and  10 
mM  was  assessed  as  de- 
scribed  in  Materials  and 
Methods.  Cells  were  either 
(front  to  back):  unstimu- 
lated, stimulated with 10 ng/ 
ml PMA for 10 min at 37°C, 
stimulated  with  the  activat- 
ing combination of CD2-spe- 
cific  mAbs  for  10  min  at 
37°C, or stimulated with a 1: 
500 dilution of the activating 
131-specific mAb  P4Gll  for 
10 min at 37°C. Data are rep- 
resentative  of a minimum of 
four different experiments. 
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Increases in F-actin Content in HL60 Transfectants 
Activation  of PI  3-K  has  also  been  implicated  in  alter- 
ations of the cytoskeleton (34, 58). Since such cytoskeletal 
rearrangements  could have an effect on cell adhesion, we 
determined whether CD2 stimulation of CD2  ÷ HL60 trans- 
fectants resulted  in actin polymerization, as measured by 
increased staining of the F-actin dye BODIPY FL-phalla- 
cidin. Fig.  11  shows that stimulation  of 11.5  transfectants 
with the activating combination of CD2-specific mAbs re- 
sults  in increased  F-actin content when compared to un- 
stimulated  cells.  Interestingly,  PMA-stimulation  of  the 
same cells failed to result in actin polymerization, suggest- 
ing that PKC activation is not involved in this cytoskeletal 
rearrangement.  A  role for PI 3-K in CD2-mediated  actin 
polymerization is suggested by the ability of wortmannin 
to inhibit the increase in F-actin content observed in CD2 ÷ 
HL60  transfectants  upon  stimulation  with  CD2-specific 
mAbs (Fig. 11). 
CD2 Stimulation of  Peripheral Blood T Cells Results in 
PI 3-K-dependent Upregulation of ill Integrin Activity 
To confirm that PI 3-K has a similar role in CD2 adhesion 
regulation in cells that normally express CD2, we assessed 
CD2-associated PI 3-K activity in CD2 ÷ peripheral  blood 
T cells. We have previously demonstrated that stimulation 
of peripheral  T  ceils  with  the  activating  combination  of 
CD2-specific mAbs results in increased [31 integrin-medi- 
ated  adhesion  of T  cells  to FN and laminin  (63).  Fig.  12 
shows that, similar to what was observed with CD2 ÷ HL60 
transfectants,  wortmannin inhibits  the increased adhesion 
of human T  cells to FN that occurs after CD2 stimulation, 
but not PMA stimulation. CD2 stimulation also resulted in 
increased actin polymerization in human T ceils that could 
be inhibited by wortmannin (data not shown). 
Immunoblotting analysis also demonstrates that CD2 in 
human T cells is constitutively associated with the p85 sub- 
unit of PI 3-K and CD2 stimulation does not result in in- 
creased  p85  association  with  CD2  (Fig.  13  A).  In  vitro 
analysis of the activity of CD2-associated PI 3-K does re- 
veal one difference between  CD2 expressed  on human T 
cells  and  CD2  expressed  on  HL60  cells.  Compared  to 
CD2 ÷ HL60 transfectants,  there is a  higher basal level of 
PI 3-K activity in CD2 immunoprecipitates  isolated from 
unstimulated  human T  cells (Fig.  13 B). However, similar 
to what was observed in HL60 transfectants, CD2 stimula- 
tion of human T  cells also results  in increased  activity of 
the CD2-associated PI 3-K (Fig. 13 B). In multiple experi- 
ments,  CD2-stimulation  consistently  resulted  in  a  1.5-2- 
fold increase in the activity of the associated PI 3-K, as as- 
sessed by quantitative analysis using a phosphorimager. 
Discussion 
Using DNA-mediated gene transfer, we have been able to 
reconstitute  the integrin regulatory activity of the human 
T  cell antigen  CD2 in a  non-T cell line,  the myelomono- 
cytic cell line HL60. Stimulation with an activating combi- 
nation of CD2-specific mAbs was able to increase binding 
of HL60 cells to FN and VCAM-1 to levels comparable to 
that seen with PMA-stimulation. Further analysis of these 
transfectants  suggest a critical role for PI 3-K in the regu- 
lation of integrin  activity by CD2.  First,  CD2-stimulated 
increases in [31 integrin activity could be completely inhib- 
ited by the PI 3-K inhibitor  wortmannin.  Second, PI 3-K 
could  be  detected  in  CD2  immunoprecipitates  prepared 
from both unstimulated  and CD2-stimulated HL60 trans- 
Figure 11.  CD2-induced  increases  in  actin  polymerization  in 
HL60  transfectants  can  be  inhibited  by  wortmannin.  HL60 
(CD2)-11.5  cells were either unstimulated, stimulated for 10 min 
at 37°C with t0 ng/ml PMA (shaded bars), or stimulated for 10 
min  at  37°C  with  the  activating  combination  of CD2-specific 
mAbs (solid bars) in the absence or presence of 100 nM wort- 
mannin. After stimulation, cells were permeabilized, labeled with 
BODIPY FL-phallacidin, and fluorescence assessed  by flow cy- 
tometry as described in Materials and Methods. All results  in a 
given experiment  are normalized to the mean channel fluores- 
cence of unstimulated HL60(CD2)-ll.5 cells, which was given an 
arbitrary value of 1. Relative F-actin contents greater than 1 indi- 
cate an increase in actin polymerization relative to unstimulated 
cells. Results of two separate experiments (out of a total of four) 
are shown. 
Figure 12.  CD2-mediated upregulation of adhesion of human T 
cells to FN is inhibited by wortmannin. Binding of peripheral hu- 
man T cells to FN (applied at I I.~g/well) was assessed in the pres- 
ence of no stimulus,  10 ng/ml PMA, or an activating combination 
of CD2-specific mAbs in the absence (shaded bars) or continuous 
presence (solid bars) of 100 nM wortmannin. Cells were activated 
for 10 min at 37°C before washing away the nonadherent cells. 
Data are representative of a minimum of three different experi- 
ments. 
The Journal of Cell Biology,  Volume 131, 1995  1876 Figure 13.  PI 3-K is associated  with CD2 and activated by CD2 
stimulation  of T cells. (Left) Unstimulated T cells or T cells stim- 
ulated with the activating combination of CD2-specific mAbs for 
10 min were lysed in PI 3-K lysis buffer, and immunoprecipitated 
with  the CD2-specific  mAb 35.1 as described  in  Materials  and 
Methods.  Immunoblotting for detection of the p85 subunit  was 
performed as described  in Fig. 8 legend.  (Right) T cells were ei- 
ther unstimulated  or stimulated  with the activating combination 
of CD2-specific  mAbs for 10 min at 37°C, lysed in PI 3-K lysis 
buffer, and then immunoprecipitated with the CD2-specific mAb 
35.1. Samples were then tested for PI 3-K activity as described  in 
Fig. 9 legend.  Quantitative analysis using a phosphorimager re- 
vealed that CD2 stimulation  of human T cells results in a 1.7-fold 
increase  in radiolabeled PIP when compared to unstimulated T 
cells. Data are representative of a minimum of four experiments. 
fectants.  Finally, while the  activity of CD2-associated PI 
3-K in unstimulated cells is negligible, CD2 stimulation re- 
sults in induction of PI 3-K activity in CD2 immunoprecip- 
itates. 
These studies provide new evidence that PI 3-K is a crit- 
ical intracellular  mediator involved in  integrin  upregula- 
tion mediated by CD2 stimulation. We propose the follow- 
ing model of CD2-mediated signaling that leads to integrin 
upregulation  that is consistent with the results presented 
in this study. It is clear from our immunoblotting experi- 
ments that PI 3-K is consitutively associated with CD2 in 
unstimulated cells but that the  associated PI 3-K is rela- 
tively  inactive.  Stimulation  of  CD2  with  the  activating 
combination of CD2-specific mAbs results in activation of 
the  already  associated  PI  3-K  but  does  not  induce  in- 
creased association of additional PI 3-K. Activation of PI 
3-K by CD2 stimulation is required for CD2-mediated in- 
creases  in  131  integrin  activity  and  leads  to  two  down- 
stream, independent PI 3-K-dependent responses: activa- 
tion of PKC and actin polymerization. This is based on the 
ability of the  PKC inhibitor  bisindolylmaleimide to  par- 
tially inhibit CD2-dependent increases in 131 integrin func- 
tion in our HL60 transfectants, as well as our finding that 
CD2 stimulation results in increased actin polymerization 
that can be inhibited by wortmannin. We propose that PI 
3-K-dependent  actin polymerization and  PKC activation 
are independent downstream events, since PMA stimula- 
tion fails to increase F-actin content in  our CD2  ÷ HL60 
transfectants.  Our  findings  on  actin  polymerization  are 
consistent with other studies that have clearly implicated 
PI  3-K  in  regulation  of the  actin  cytoskeleton  (34,  58). 
Since CD2 stimulation has previously been shown to result 
in  PKC  activation  (2),  an  alternative  possibility  is  that 
CD2 stimulation results in an independent pathway of up- 
regulation of [31 integrin function that involves direct acti- 
vation of PKC independent of PI 3-K activation. However, 
our model proposing that PKC activation is downstream 
of PI 3-K activation in the CD2 integrin regulatory path- 
way is consistent with the fact that: (a) the PKC inhibitor 
bisindolylmaleimide is much less effective than wortman- 
nin  in  inhibiting  CD2-dependent  increases  in  integrin 
function;  and  (b)  studies  in  other  systems have  demon- 
strated that the lipid products generated by PI 3-K activity 
can activate certain PKC isoforms in vitro (44, 73). 
Previous studies  of T  cell integrin  regulators have not 
implicated PI 3-K in this regulatory event, although other 
intracellular mediators such as tyrosine kinases, protein ki- 
nase A, and pertussis toxin-sensitive G proteins have been 
implicated (4, 12, 17, 61). However, studies of mast cell ad- 
hesion to FN have recently shown that treatment of mast 
cells with stem cell factor, the ligand for the c-kit growth 
factor receptor, can upregulate 131 integrin-mediated mast 
cell adhesion to FN (16, 36). Furthermore, the c-kit recep- 
tor associates with PI 3-K in a  tyrosine phosphorylation- 
dependent manner and integrin upregulation on mast cells 
induced by stem cell factor has recently been shown to be 
dependent on c-kit-associated PI 3-K activity (57). Thus, it 
is now clear that an additional cellular response mediated 
by PI 3-K is  alterations  in  cell  adhesion.  T  cell integrin 
function  has  recently been  shown  to  be  upregulated  by 
hepatocyte growth factor (HGF), and this increase in ac- 
tivity correlated with HGF-induced increases in actin po- 
lymerization  (1).  Although  the  HGF receptor, the  c-met 
oncogene,  does not  appear to be  expressed in  human T 
cells (t), HGF binding to the c-met receptor in other cell 
types has been shown to result in increased tyrosine kinase 
activity, as well as tyrosine phosphorylation-dependent as- 
sociation and activation of PI 3-K (21). It will be important 
in the future to determine if other growth factor receptors 
that have been shown to associate with PI 3-K might also 
be involved in regulating integrin functional activity. 
We have also previously shown that antibody crosslink- 
ing of the  CD28 antigen expressed on human T  cells re- 
suits in increased 131 and [32 integrin function (40, 61). In- 
terestingly, recent studies of CD28 function have revealed 
that CD28 associates with PI 3-K in a tyrosine phosphory- 
lation-dependent  manner (45, 51, 74), and PI 3-K associ- 
ated with CD28 is necessary for CD28-mediated produc- 
tion  of  IL-2  (45).  The  ability  of wortmannin  to  inhibit 
CD28-induced  increases in  131-mediated  adhesion  to FN 
suggests a role for PI 3-K in the adhesion regulatory prop- 
erties of this receptor as welt (T. Zell, S. W. Hunt III, J. L. 
Mobley, and Y. Shimizu, manuscript in preparation). We 
have  also  recently found  that  PI 3-K  associates in  a  ty- 
rosine phosphorylation-dependent  manner with the  CD7 
antigen and that wortmannin can completely inhibit CD7- 
induced increases in [31 integrin activity on human T  cells 
(A. S. H. Chan, J. L. Mobley, and Y. Shimizu, manuscript 
in preparation).  Since the  submission of this manuscript, 
Shimizu et al. P13-K and CD2 Adhesion Regulation  1877 two studies  provide evidence that  regulation  of integrin 
function induced  by chemokines may also be dependent 
on  PI  3-K.  In  one  study,  treatment  of  T  cells  with 
RANTES, a potent T  cell chemoattractant, was found to 
result in increased PI 3-K activity (75). RANTES-induced 
T cell chemotaxis was also found to be inhibited by wort- 
mannin (75). In the second study, a novel pll0 PI 3-K sub- 
unit was identified  that could be activated in vitro by G 
proteins (69). This is an intriguing finding, since treatment 
of T cells with G protein inhibitors, such as pertussis toxin, 
was found to inhibit activation-induced increases in inte- 
grin  activity  that  occur  during  lymphocyte  interactions 
with endothelial cells in vivo (4). Thus, there is increasing 
evidence to suggest that the activity of other integrin regu- 
lators expressed on T  cells may also be dependent on the 
induction of associated PI 3-K activity. 
Our  studies  with  CD2-induced  adhesion  regulation  in 
normal CD2 ÷ T cells are consistent with our findings using 
CD2 ÷  HL60 transfectants.  CD2-induced  increases  in  131 
integrin activity and actin polymerization in T cells can be 
inhibited by wortmannin. PI 3-K is associated with CD2 in 
T  cells and CD2 stimulation increases CD2-associated PI 
3-K activity. However, two differences were observed be- 
tween T  cells and HL60 cells with regard to CD2 and PI 
3-K. First,  wortmannin  did  not  completely inhibit  CD2- 
induced increases in adhesion of T cells to FN at doses that 
completely  inhibited  CD2-induced  adhesion  of  HL60 
transfectants.  This suggests that  CD2 may also use  a  PI 
3-K-independent signaling pathway in human T  cells for 
regulating 131 integrin activity. Second, there was a greater 
level of basal PI 3-K activity in CD2 immunoprecipitates 
from  unstimulated  T  cells  compared  to  unstimulated 
HL60 cells. The reason for these differences is not clear at 
present, although the reported physical and functional as- 
sociation between CD2 and the CD3/T cell receptor com- 
plex (5, 10) suggests that the presence of the T cell recep- 
tor in human T  cells may be an important factor. This is 
currently being investigated. 
PI  3-K  associates  with  the  c-kit  receptor,  CD28,  and 
many other cell surface receptors via the SH2 domain of 
the p85 subunit of PI 3-K associating with a specific phos- 
photyrosine-containing amino acid motif in the receptor's 
cytoplasmic domain  (47,  66).  Thus,  such SH2-dependent 
association of PI 3-K requires that receptor activation in- 
duce some associated tyrosine kinase activity. The associa- 
tion of CD2 with PI 3-K in HL60 cells does not appear to 
be mediated by the p85 SH2 domain. First, the CD2 cyto- 
plasmic domain lacks any tyrosine residues (55).  Second, 
our results demonstrate that PI 3-K is associated with CD2 
in unstimulated cells and CD2 stimulation fails to increase 
the amount of associated PI 3-K. Therefore, the mecha- 
nism by which  CD2  associates with  PI 3-K does not in- 
volve tyrosine phosphorylation-dependent  association of 
p85 with CD2. 
Although the mode of association of CD2 with PI 3-K 
remains undefined, several lines of evidence suggest that 
PI 3-K may associate with CD2 via an SH3-dependent in- 
teraction.  First,  the  p85  subunit  of PI 3-K possesses  an 
SH3 domain (47) and an SH3-dependent interaction of PI 
3-K  with  the  motor protein  dynamin  has  been  demon- 
strated  (19).  Second,  SH3  domains  have been shown  to 
mediate  protein-protein  interactions  by binding  to  pro- 
line-rich sequences (47). Third,  the CD2 cytoplasmic do- 
main is rich in proline residues  that might be capable of 
mediating SH3 domain interactions (55). The role of two 
repeated PPPGHR motifs in the CD2 cytoplasmic domain 
in integrin regulation is of particular interest, since dele- 
tion of either or both of these motifs has been shown to 
impair CD2-mediated production of IL-2 and increases in 
cyclic AMP (6). We are currently using our system to de- 
termine the effects of mutations in the  CD2 cytoplasmic 
domain  on  association with  PI  3-K  as  well  as  on  CD2- 
induced  upregulation  of integrin  activity. These ongoing 
studies  will  allow us  to precisely map  the  region  in  the 
CD2 cytoplasmic domain mediating the  association with 
PI 3-K and whether this association is dependent  on the 
p85 SH3 domain. The functional consequences of an SH3- 
mediated interaction of PI 3-K with CD2 as compared to 
the  more  well-characterized  SH2-dependent  interaction 
could be quite significant. Since the p85 subunit contains 
SH2 domains and an SH3 domain, association of CD2 with 
PI 3-K via the SH3 domain would allow the CD2/PI 3-K 
complex to potentially  associate with  other  intracellular 
molecules via the free SH2 domains in the p85 subunit. 
Binding of the SH3 domains of the lyn and fyn tyrosine 
kinases to a  proline-rich region in the p85  subunit  of PI 
3-K has recently been shown to result in increased PI 3-K 
activity (48). These results suggest that SH3 domain bind- 
ing to these proline-rich sequences in p85 is sufficient by 
itself to activate PI 3-K, although the mechanism by which 
this occurs is unknown. This is distinct from our findings of 
CD2 association with PI 3-K, since the p85 subunit can be 
found to be associated with CD2 in unstimulated cells but 
is enzymatically inactive. Thus, both the mode of associa- 
tion of PI 3-K with CD2 as well as the regu!ation of PI 3-K 
activity by CD2 may be distinct from other previously de- 
scribed PI 3-K-associated receptor systems. 
In summary, we have demonstrated a role for PI 3-K in 
the ability of the CD2 antigen to function  as an integrin 
regulator. The association of CD2 with PI 3-K does not oc- 
cur via a tyrosine phosphorylation-dependent mechanism 
and may involve a novel mode of protein-protein interac- 
tion. Furthermore, our ability to reconstitute CD2 integrin 
regulatory activity in a non-T cell line suggests that T cells 
and HL60 ceils share common intracellular pathways in- 
volved in integrin regulation. This is consistent with other 
studies demonstrating reconstitution of the integrin regu- 
latory activity of the f-met-leu-phe receptor from neutro- 
phils in a lymphoma cell line (28). Finally, it should be pos- 
sible  to  use  this  system  to  systematically  analyze  the 
structural requirements for the function of CD2 as well as 
other integrin regulators. Such studies should lead to a de- 
termination of whether PI 3-K represents a common intra- 
cellular mediator involved in regulation of integrin func- 
tional activity. 
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